Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

576 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-04

Study Completion Date

2021-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Characterization of fungal infections in COVID-19 infected and mechanically ventilated patients in ICU

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Staging Candidiasis in ICU Patients

NCT01322698

Candidiasis

COMPLETED

COVID-19 and ICU-acquired MDR Bacteria

NCT04378842

Sars-CoV2 Critical Illness

COMPLETED

Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients

NCT01495039

Fungal Prophylaxis Candida Infection Critical Illness +1 more

COMPLETED PHASE4

Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients

NCT03413293

Nosocomial Infection

UNKNOWN

How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?

NCT04348227

Ventilator Associated Pneumonia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, ICU patients with ARDS, whatever the etiology, are not systematically screened for the detection of respiratory fungal infections.

Here, the protocol will be in two steps:

First step

COVID-19 patients hospitalized in ICU for ARDS will benefit for a systematic screening with a fungal respiratory syndromic panel once or twice a week from entry to discharge from ICU, with minimum 3 samples when discharge occurs after 15 days::

* Sample: tracheal aspiration, bronchial aspiration, BAL
* Fungal respiratory panel: samples will be processed in each lab for culture without direct examination nor stained smears, and real-time PCR will be performed for Aspergillus, Pneumocystis jirovecii and mucormycetes
* Results will be given to ICU in order to optimize the management of the patient Second step

Complementary analysis will be performed in order to finalize the diagnostic and to differentiate between colonization and infection, with:

* Serum detection of galactomannan and serum Aspergillus PCR in case of positive respiratory sample for Aspergillus
* Serum/plasma beta-D-glucan detection in case of positive respiratory sample for Pneumocystis jirovecii
* Serum mucorales PCR in case of positive respiratory sample for mucorales This second step is possible in most of the labs, but when necessary a confirmation test can be externalized. A process of DNA transmission to a reference lab within each region will be implemented.

This second step will allow to classify infections as probable or proven according to international recommendations.

Case report form (CRF) A short but standardized CRF will be proposed to all centers in order to collect demographic data and the essential clinical and laboratory data during the survey.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ICU patients COVID-19 diagnosed by RT-PCR
* Intubated and mechanically ventilated patients
* Adult patients
* Patients (or legal representative) informed on the research without opposition

* Patients \<18 years old
* People of full age who are the subject of a judicial safeguard,

Exclusion Criteria

* Patient, or legal representative opposing the pursuit of the research
* Patients under judicial protection will be excluded as soon as the investigator becomes aware of their status.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No